SAB-142 Phase 1 Data Shows C-Peptide Preservation in Type 1 Diabetes Patients
Summary
SAB Biotherapeutics reported encouraging Phase 1 data for SAB-142, showing C-peptide preservation in Type 1 Diabetes patients, supporting its disease-modifying potential.
Key Events
-
Positive Phase 1 Data for SAB-142
Additional data from the Phase 1 HUMAN trial showed SAB-142 treated participants (n=4) had no decrease in C-peptide levels at Day 120 compared to baseline, while the placebo participant showed a decrease.
-
C-Peptide Preservation Observed
The data indicates early signals of C-peptide preservation, consistent with the anticipated mechanism of action for SAB-142 in adult patients with established Type 1 Diabetes.
-
Supports Phase 2b Advancement
These findings further support the advancement of SAB-142 into the registrational Phase 2b SAFEGUARD trial, which was previously announced in the 10-K filed yesterday.
Analysis
SAB Biotherapeutics announced additional positive Phase 1 data for its lead candidate, SAB-142, in adult patients with established Type 1 Diabetes. The data demonstrated early signals of C-peptide preservation, a key indicator of beta cell function, which aligns with the drug's anticipated mechanism of action. This positive clinical update provides further validation for SAB-142 as it progresses into a registrational Phase 2b trial, reinforcing investor confidence in the program's potential to modify the course of T1D.
At the time of this filing, SABS was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.8M. The 52-week trading range was $1.00 to $6.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.